Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors

Abstract excerpt

BACKGROUND: Impairment of homologous recombination (HR) is found in close to 50 % of ovarian and breast cancer. Tumors with BRCA1 mutations show increased expression of the Insulin-like growth factor type 1 receptor (IGF-1R). We previously have shown that inhibition of IGF-1R results in growth inhibition and apoptosis of ovarian tumor cells. In the current study, we aimed to investigate the correlation between HR...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Growth Hormone and Insulin-like Growth Factors
• Share to Metabolism, Diabetes, and Cancer
• Share to PARP inhibition in cancer therapy